Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce cardiovascular events and mortality in T2DM patients with a risk of cardiovascular disease. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.